详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Targeting HLA-E in Lung Cancer: The Therapeutic Potential of IRF5-Engineered M1-Macrophage-Derived Exosomes

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Oncology, Beijing Anzhen Nanchong Hospital, Capital Medical University (Nanchong Central Hospital), The Second Clinical Medical College of North Sichuan Medical College, Nanchong, Sichuan, China. [2]Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing Cancer Hospital, Chongqing Cancer Institute, Chongqing, China. [3]Department of Clinical Laboratory, Beibei Traditional Chinese Medical Hospital, Chongqing, China.

出处：

DOI：

ISSN：

关键词： exosome HLA-E lung cancer macrophage transcription factor

摘要：

Immunotherapy is a pivotal approach in the treatment of lung cancer. Although HLA-E is a potential target for tumor immunotherapy, its role in lung cancer remains unclear. Previous studies have identified the transcription factor IRF5 as a characteristic gene of M1-like macrophages, highlighting its crucial role in promoting antitumor immune responses. In this study, we developed an engineered M1-like macrophage exosomes expressing IRF5 (IRF5 M1-exos) and demonstrated their ability to inhibit proliferation, migration, and invasion of lung cancer cells. Moreover, our experiments using a nude mouse model revealed that IRF5 M1-exos exerted potent therapeutic effects by effectively suppressing tumor growth. Notably, the mechanism by which IRF5 exerts its antitumor function through HLA-E regulation in lung cancer has not been fully elucidated. Here, we identified HLA-E as a downstream target gene of IRF5 and demonstrated that the overexpression of HLA-E can counteract the tumor-promoting effects induced by si-IRF5 M1-exos. These results suggest that M1 macrophage-derived exosomes, enriched with the transcription factor IRF5, exhibit potent antitumor activity by up-regulating HLA-E in lung cancer cells. Therefore, IRF5 M1-exos represent an attractive therapeutic strategy for lung cancer.© 2024 The Author(s). The Clinical Respiratory Journal published by John Wiley & Sons Ltd.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 4 区医学

小类 | 4 区呼吸系统

第一作者：

第一作者机构： [1]Department of Oncology, Beijing Anzhen Nanchong Hospital, Capital Medical University (Nanchong Central Hospital), The Second Clinical Medical College of North Sichuan Medical College, Nanchong, Sichuan, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Hematopoietic Transcription Factor RUNX1 is Essential for Promoting Macrophage-Myofibroblast Transition in Non-Small-Cell Lung Carcinoma [2]Activating transcription factor 3 promotes malignance of lung cancer cells in vitro. [3]Activating transcription factor 3 promotes malignance of lung cancer cells in vitro. [4]Inhibition of PKA/CREB1 pathway confers sensitivity to ferroptosis in non-small cell lung cancer [5]Identification of the Novel Tooth-Specific Transcription Factor AmeloD. [6]High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer [7]M2 macrophage-derived exosome-functionalized topological scaffolds regulate the foreign body response and the coupling of angio/osteoclasto/osteogenesis [8]HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles [9]Transcription factor KLF16 activates MAGT1 to regulate the tumorigenesis and progression of breast cancer [10]Transcriptional inhibition of p21WAF1/CIP1 gene (CDKN1) expression by survivin is at least partially p53-dependent: evidence for survivin acting as a transcription factor or co-factor.